Checking a protein marker in adults with locally advanced cervical cancer
Studies whether an immunohistochemistry test of a protein predicts cancer returning in cervical cancer.
Plain-language title generated from the registry record
Registry title: Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
Key facts
- Where
- Nîmes, FranceSee the site
Where in France
- CHU de NîmesNîmes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Nīmes
- Trial code
- NCT06147960
- Record updated
- 22 June 2026
- Original description
Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.Read full original descriptionShow less
Evaluation of the Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on the 24-month Recurrence Rate in Locally Advanced Cervical Cancer
Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.
Inclusion: Patients treated with the exclusive radio-chemotherapy combination for locally advanced cervical carcinoma (stage Ib-IVb according to FIGO classification); Patients aged ≥ 18 years; Patients with a minimum of 2 years post-treatment follow-up; Patients for whom the initial biopsy specimen (before treatment) is available; Patients who have not indicated that they do not wish to participate in the study; Patients affiliated to or benefiting from a health insurance scheme.
Exclusion: Patients under court protection, guardianship or curatorship.